So far, already three ADCs (the anti-CD30 brentuximab vedotin, the anti-CD79 polatuzumab vedotin, and the anti-CD19 loncastuximab tesirine) have been approved for lymphoma patients. This evidence concerns the gene TNFRSF8 and lymphoma.